These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 34138908)
21. A decision making approach to assessing critical appraisal skills. Schwartz A; Hupert J Med Teach; 2005 Jan; 27(1):76-80. PubMed ID: 16147775 [TBL] [Abstract][Full Text] [Related]
22. Toward evidence-based medical statistics. 2: The Bayes factor. Goodman SN Ann Intern Med; 1999 Jun; 130(12):1005-13. PubMed ID: 10383350 [TBL] [Abstract][Full Text] [Related]
23. Evidence-based medicine as Bayesian decision-making. Ashby D; Smith AF Stat Med; 2000 Dec; 19(23):3291-305. PubMed ID: 11113960 [TBL] [Abstract][Full Text] [Related]
24. The New FDA Real-World Evidence Program to Support Development of Drugs and Biologics. Klonoff DC J Diabetes Sci Technol; 2020 Mar; 14(2):345-349. PubMed ID: 30862182 [TBL] [Abstract][Full Text] [Related]
25. Real-World Evidence: Useful in the Real World of US Payer Decision Making? How? When? And What Studies? Malone DC; Brown M; Hurwitz JT; Peters L; Graff JS Value Health; 2018 Mar; 21(3):326-333. PubMed ID: 29566840 [TBL] [Abstract][Full Text] [Related]
26. Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions. Akhras KS; Alsheikh-Ali AA; Kabbani S Expert Rev Pharmacoecon Outcomes Res; 2019 Jun; 19(3):245-250. PubMed ID: 30626231 [TBL] [Abstract][Full Text] [Related]
27. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia. Webster J; Smith BD Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609 [TBL] [Abstract][Full Text] [Related]
28. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. Chan K; Nam S; Evans B; de Oliveira C; Chambers A; Gavura S; Hoch J; Mercer RE; Dai WF; Beca J; Tadrous M; Isaranuwatchai W BMJ Open; 2020 Jan; 10(1):e032884. PubMed ID: 31915169 [TBL] [Abstract][Full Text] [Related]
29. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation. Breckenridge AM; Breckenridge RA; Peck CC Br J Clin Pharmacol; 2019 Sep; 85(9):1874-1877. PubMed ID: 31290181 [TBL] [Abstract][Full Text] [Related]
30. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations. Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138 [TBL] [Abstract][Full Text] [Related]
31. The "Coming of Age" of Real-World Evidence in Drug Development and Regulation. Honig PK Clin Pharmacol Ther; 2022 Jan; 111(1):11-14. PubMed ID: 34914104 [TBL] [Abstract][Full Text] [Related]
32. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
33. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions. Wu J; Wang C; Toh S; Pisa FE; Bauer L Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065 [TBL] [Abstract][Full Text] [Related]
34. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Franklin JM; Glynn RJ; Martin D; Schneeweiss S Clin Pharmacol Ther; 2019 Apr; 105(4):867-877. PubMed ID: 30636285 [TBL] [Abstract][Full Text] [Related]
35. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model. Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505 [TBL] [Abstract][Full Text] [Related]
36. Real-World Evidence in Healthcare Decision Making: Global Trends and Case Studies From Latin America. Justo N; Espinoza MA; Ratto B; Nicholson M; Rosselli D; Ovcinnikova O; García Martí S; Ferraz MB; Langsam M; Drummond MF Value Health; 2019 Jun; 22(6):739-749. PubMed ID: 31198192 [TBL] [Abstract][Full Text] [Related]
37. Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs. Thieffry S; Klein P; Baulac M; Plumb J; Pelgrims B; Steeves S; Borghs S Epilepsia; 2020 Apr; 61(4):595-609. PubMed ID: 32201951 [TBL] [Abstract][Full Text] [Related]
38. [Real-world evidence : Benefits and limitations in multiple sclerosis research]. Ziemssen T; Rothenbacher D; Kuhle J; Berger T Nervenarzt; 2017 Oct; 88(10):1153-1158. PubMed ID: 28776214 [TBL] [Abstract][Full Text] [Related]
39. Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetReal. Makady A; Stegenga H; Ciaglia A; Debray TP; Lees M; Happich M; Ryll B; Abrams K; Thwaites R; Garner S; Jonsson P; Goettsch W J Comp Eff Res; 2017 Sep; 6(6):485-490. PubMed ID: 28857631 [TBL] [Abstract][Full Text] [Related]
40. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]